Global Dermatology Partnering Deals Collection 2014-2020: Comprehensive Access to 750+ Deals Entered Into by the World's Leading Biopharma Companies - ResearchAndMarkets.com

The "Global Dermatology Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

This report provides an understanding and access to the dermatology partnering deals and agreements entered into by the world's leading healthcare companies.

In-depth understanding of Gastrointestinal deal trends since 2014
Access Gastrointestinal deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Gastrointestinal partner companies
Comprehensive access to over 750 links to actual Gastrointestinal deals entered into by the world's biopharma companies
Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Gastrointestinal opportunities
Uncover companies actively partnering Gastrointestinal opportunities

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dermatology deals.

The report presents financial deal terms values for Dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of dermatology dealmaking trends.

Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in dermatology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading dermatology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to dermatology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2014. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

3D Systems
3M Critical & Chronic Care Solutions
23andMe
Abbvie
Accelis Pharma
AccuTec Blades
Acelity
Acell
Aclaris Therapeutics
Actelion
ADB International Group
Adhesys Medical
Advanced BioScience Laboratories
Advanced Medical Solutions
Advanced Plasma Products
Advanz Pharma
Aesthetic Management Partners
Afinity Life Sciences
Aghraas-Cigalah
Air Force Research Laboratory
AiVita Biomedical
Akaal Pharma
Alat Medika Indonesia
Alibaba Health
ALK-Abello
Allergan
Allergan (name changed from Actavis)
Alliance Pharma
Alliqua Biomedical
AlloSource
Almirall
Alpha Pharma
Alvotech
Amarantus BioSciences
American Academy of Professional Coders
American Red Cross
American Skin Association
Amgen
AMI
AMNIOX
Amor (Suzhou) Medical Sci-Tech
AMSilk
Amyris
ANANDA Scientific
Andrew Technologies
Angelini Pharma
AnGes MG
Angionetics
Anika Therapeutics
ANI Pharmaceuticals
Anteis
Anterios
Antibe Therapeutics
AOTI
APL
Applied Biology
APR Applied Pharma Research
Apria Healthcare Group
Aqua Pharmaceuticals
Aralez Pharmaceuticals
Aratana Therapeutics
Arcutis Biotherapeutics
arGEN-X
Arrevus
Arrien Pharmaceuticals
Arsenal Medical
Arthrex
Art of Technology
Aslan Pharma
Astellas Pharma
Astion Pharma
AstraZeneca
ATG Allied Technologies
Athenex
Atopix
Aucta Pharmaceuticals
Austen BioInnovation Institute in Akron (ABIA)
Auven Therapeutics
Avalon Pharmaceuticals
Avaria Health & Beauty
Avita Medical
AvKARE
Axcelon Dermacare
Axonlab
Axxess Pharma
Azitra
Back-A-Line
BASF
Basilea Pharmaceutica
Bassett Salon Solutions
Bausch & Lomb
Bavarian Ministry for Economic Affairs and Media
Energy and Technology
Bayer
Baylor Research Institute
B Braun
Beiersdorf
Bellus Health
Ben-Gurion University
Berkshire Sterile Manufacturing
Berlin-Brandenburg Center for Regenerative Therapies
Berlin Chemie
Best Choice
BexPharm
BGN Technologies
Bill and Melinda Gates Foundation
BioCad Holding
Biocon
BioCryst Pharmaceuticals
BioDerm
BioDlogics
Biogen
BiolineRX
Biomedical Advanced Research and Development Authority
BIOMEDX Group
BioMed X Innovation Center
Biometrix
Biomillenia
Bioniz Therapeutics
Bionpharma
Biophage Pharma
BioPharm Group International
Bioskin
Biosolution
BirchBioMed
Bloomage BioTechnology
BMG Pharmaceuticals
Boehringer Ingelheim
Boragen
Boston Pharmaceuticals
Boston Topicals
BoyaLife
Bpifrance
Brickell Biotech
Brigham and Women's Hospital
Bright Future Pharmaceutical Lab
BSN Medical
Cadila Pharmaceuticals
CALECIM Cosmeceuticals
Caliber Imaging & Diagnostics
Can-Fite BioPharma
CANbridge Life Sciences
Candela
and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/jdfg9z

View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005397/en/

Market News and Data brought to you by Benzinga APIs